Work

Rapid Regression of Rare Sub-Cutaneous Metastasis in Urothelial Carcinoma Patient Treated with Enfortumab Vedotin Plus Pembrolizumab: A Case Report

Year: 2026

Type: article

Abstract: Bladder cancer is a common urological malignancy, predominantly affecting older adults, and metastatic disease is associated with poor prognosis. We present the case of a 70-year-old woman with metastatic urothelial carcinoma presenting as a right subcutaneous axillary mass. First-line treatment with enfortumab vedotin, an anti–Nectin-4 antibody–drug conjugate, combined with the PD-1 inhibitor pembrolizumab resulted in a rapid and clinically significant regression of the lesion. This case illustrates a rare presentation of subcutaneous metastasis in urothelial carcinoma, suggestive of aggressive tumor biology. The dramatic response to enfortumab vedotin plus pembrolizumab underscores the potential efficacy of this combination in patient's ineligible for cisplatin-based chemotherapy. Early systemic therapy proved effective in controlling metastatic progression, even in the set setting of renal impairment and advanced age.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.19397079

Author: Roberta Giorgione1,2*, Lorenzo Di Stefano1,2, Carla Amato1,3, Marinella Micol Mela1, Fabrizio Di Maida2,4, Andrea Minervini2,4, Serena Pillozzi5, Giandomenico Roviello1,3, Lorenzo Antonuzzo1,2

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7148818918

FWCI:

Cites:

Cited by:

Related to: